Anbio Biotechnology (NNNN) Stock
Anbio Biotechnology (NNNN) closed at $3.65 on Nov 17, 2026; its Tenet Score is 37 of 100 against 340 Healthcare peers.
36 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $3.65
- Nov 17, 2026
- Market cap
- $558.3M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- P/E
- 87.2×
- fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
- 52-week range
- 3.09 – 44.73
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 37/100
- Weak · 340 Healthcare peers
Industry: In Vitro, in Vivo Diagnostic Substances
Anbio Biotechnology scores 37/100. Weak. Strongest on financial health, growth is the soft spot, trading at 87× earnings versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ~ Buffett Quality
- ✕ Piotroski F-Score
- ✓ Munger Compounders
- ✕ Magic Formula
- ✕ Graham Defensive
- ✕ Quality Compounder
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift toward…
Similar-sized companies in In Vitro, in Vivo Diagnostic Substances
The 1 company in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| QuidelOrtho CorporationQDEL | 44 | $701.4M |
Common questions
What sector and industry is Anbio Biotechnology in?
Anbio Biotechnology is in the Healthcare sector and the In Vitro, in Vivo Diagnostic Substances industry.
What is Anbio Biotechnology's Tenet Score?
Anbio Biotechnology's Tenet Score is 37 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

